VEGFA and renal cell carcinoma: In the immuno‐oncology era of RCC, combining VEGF‐TKIs with anti‐programmed death 1 (PD‐1) monoclonal antibodies or anti‐programmed death‐ligand 1 (PD‐L1) antibodies has been found to provide better efficacy than VEGF‐TKI monotherapy.